On January 6, 2021, Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data on ivermectin before the National Institutes of Health (NIH) Treatment Guidelines Panel.

Authors: Cangiano B, Fatti LM, D anesi L, Croci M, Vitale G. PMID: PMC7803543 DOI: 10.18632/aging.202307 Abstract Introduction: The COVID-19 pandemic caused an increased mortality in nursing homes due to its quick spread and the age-related high lethality. Results: We observed a two-month mortality of 40%, compared to 6.4% in the previous year. This increase [...]

Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.

Authors: Risch HA PMID: 32458969 PMCID: PMC7546206 DOI: 10.1093/aje/kwaa093 Abstract More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it. High-risk patients with progressing symptomatic disease currently have only hospitalization treatment, with its high mortality, available to them. [...]

More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it.

Authors:Annweiler C, Hanotte B, de L'Eprevier CG, Sabatier JM, Lafaie L. PMID:PMC7553119 doi: 10.1016/j.jsbmb.2020.105771 Abstract Vitamin D may be a central biological determinant of COVID-19 outcomes. The objective of this quasi-experimental study was to determine whether bolus vitamin D3 supplementation taken during or just before COVID-19 was effective in improving survival among frail elderly nursing-home [...]

Authors: Cadegiani FA, Goren A, Wambier CG, McCoy J doi: https://doi.org/10.1101/2020.10.05.20206870 Abstract Background While COVID-19 remains largely unclear and mortality continues to raise, early effective approaches prior to complications lack, as well as researches for characterization and therapeutical potential options in actual early COVID-19. Although females seem to be less affected than females, hyperandrogenic (HA) [...]

Authors: Castillo ME, Costa LM, Barrios JM, Diaz JF, Miranda JL, Bouillon R et al. PMID: 32871238 PMCID: PMC7456194 DOI: 10.1016/j.jsbmb.2020.105751 Abstract Objective: The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly increase serum [...]

Authors: Chowdhury AT, Shahabz M, Karim MR, Islam J, Guo D, He D. DOI: https://doi.org/10.21203/rs.3.rs-38896/v1 Abstract Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease. In this [...]

Authors: Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM. doi: https://doi.org/10.1101/2020.07.07.20145979 Abstract Background To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect. Objectives To assess the effectiveness of ivermectin (IVM) as add-on therapy to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of [...]